Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bionano GenomicsMEX:BNGO 61 Net Debt Paydown Yield % is 28.92% as of Jul. 27, 2026. GuruFocus rates MEX:BNGO with a GF Score™ of 61/100 and a GF Value™ of MXN26.13 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 767 Medical Devices & Instruments companies, Bionano Genomics ranks better than 97.26% on this metric.
Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt.
As of today, Bionano Genomics's Net Debt Paydown Yield % was 28.92%.
Bionano Genomics (MEX:BNGO) Net Debt Paydown Yield % Explanation
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.
In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.
Bionano Genomics Net Debt Paydown Yield % Related Terms
Bionano Genomics Net Debt Paydown Yield % Historical Data
* Premium members only.
The historical data trend for Bionano Genomics's Net Debt Paydown Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:BNGO vs RGNT, UEEC, FEMY: Net Debt Paydown Yield % Comparison
For the Medical Instruments & Supplies subindustry, Bionano Genomics's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bionano Genomics Net Debt Paydown Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bionano Genomics's Net Debt Paydown Yield % distribution charts can be found below:
* The bar in red indicates where Bionano Genomics's Net Debt Paydown Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
What does a Net Debt Paydown Yield % of 28.92% mean?
Bionano Genomics (MEX:BNGO) has a Net Debt Paydown Yield % of 28.92% as of Jul. 27, 2026. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Bionano Genomics and its competitors. According to the industry distribution chart, Bionano Genomics ranks #21 out of 767 companies in the Medical Devices & Instruments industry, placing it in the top 2.7%.
Is Bionano Genomics' Net Debt Paydown Yield % too high?
Bionano Genomics' current Net Debt Paydown Yield % is 28.92%. The Medical Devices & Instruments industry median Net Debt Paydown Yield % is 0.01. Bionano Genomics' value of 28.92% is 289100% above this industry median. Based on the distribution chart, Bionano Genomics ranks #21 out of 767 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Bionano Genomics has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bionano Genomics' Net Debt Paydown Yield % compare to RGNT and UEEC?
According to the Medical Devices & Instruments industry distribution chart, Bionano Genomics ranks #21 out of 767 companies for Net Debt Paydown Yield %. This places Bionano Genomics in the top 3% of its industry — outperforming the majority of peers. The industry median Net Debt Paydown Yield % is 0.01. Bionano Genomics' value of 28.92% is 289100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Debt Paydown Yield % for a Medical Devices & Instruments company?
The median Net Debt Paydown Yield % among Medical Devices & Instruments companies is 0.01, based on 767 companies in the industry. Companies in the top quartile (top 25%) have a Net Debt Paydown Yield % significantly above this median, while those in the bottom quartile fall well below. However, Net Debt Paydown Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bionano Genomics's current Net Debt Paydown Yield % of 28.92% is 289100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Debt Paydown Yield % mean?
A high Net Debt Paydown Yield % can signal that a stock is expensive relative to its fundamentals. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Bionano Genomics and its competitors. For the Medical Devices & Instruments industry, the median Net Debt Paydown Yield % is 0.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bionano Genomics's current Net Debt Paydown Yield % is 28.92%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionano Genomics stock overvalued right now?
Based on GuruFocus' analysis, Bionano Genomics (MEX:BNGO) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN26.13, compared to a current price of MXN20.00 — trading 23.5% below its estimated fair value. The current Net Debt Paydown Yield % is 28.92% and 289100% above the Medical Devices & Instruments industry median of 0.01. Bionano Genomics' overall GF Score™ is 61/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Debt Paydown Yield % calculated?
Net Debt Paydown Yield % is calculated from a company's financial statements. For Bionano Genomics (MEX:BNGO), the current Net Debt Paydown Yield % is 28.92% as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bionano Genomics (MEX:BNGO) Overvalued in 2026?
Based on GuruFocus' analysis, Bionano Genomics stock appears to be undervalued.
The current stock price of MXN20.00 is trading 23.5% below its estimated GF Value™ of MXN26.13.
GuruFocus considers Bionano Genomics to be Modestly Undervalued.
Key valuation signals for MEX:BNGO:
Net Debt Paydown Yield %: 28.92%
GF Value™: MXN26.13 vs. price of MXN20.00 (23.5% below fair value)
Industry Position: 289100% above the Medical Devices & Instruments median (#21 of 767)
No single metric tells the full story. See the MEX:BNGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.
61GF Score
Get the complete analysis for MEX:BNGO
Net Debt Paydown Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:BNGO has been successfully added to your 
